- Home
- CNMD vs TRVI Comparison
CNMD vs TRVI Comparison
Compare CNMD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- TRVI
- Stock Information
- Founded
- CNMD 1970
- TRVI 2011
- Country
- CNMD United States
- TRVI United States
- Employees
- CNMD N/A
- TRVI N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CNMD Health Care
- TRVI Health Care
- Exchange
- CNMD Nasdaq
- TRVI Nasdaq
- Market Cap
- CNMD 1.5B
- TRVI 1.4B
- IPO Year
- CNMD 1987
- TRVI 2019
- Fundamental
- Price
- CNMD $44.00
- TRVI $11.66
- Analyst Decision
- CNMD Hold
- TRVI Strong Buy
- Analyst Count
- CNMD 5
- TRVI 9
- Target Price
- CNMD $59.80
- TRVI $20.72
- AVG Volume (30 Days)
- CNMD 341.7K
- TRVI 1.6M
- Earning Date
- CNMD 11-05-2025
- TRVI 11-10-2025
- Dividend Yield
- CNMD 1.82%
- TRVI N/A
- EPS Growth
- CNMD 12.82
- TRVI N/A
- EPS
- CNMD 3.54
- TRVI N/A
- Revenue
- CNMD $1,326,244,000.00
- TRVI N/A
- Revenue This Year
- CNMD $6.73
- TRVI N/A
- Revenue Next Year
- CNMD $5.45
- TRVI N/A
- P/E Ratio
- CNMD $12.43
- TRVI N/A
- Revenue Growth
- CNMD 3.94
- TRVI N/A
- 52 Week Low
- CNMD $42.50
- TRVI $2.36
- 52 Week High
- CNMD $78.00
- TRVI $11.68
- Technical
- Relative Strength Index (RSI)
- CNMD 36.37
- TRVI 75.27
- Support Level
- CNMD $43.64
- TRVI $10.30
- Resistance Level
- CNMD $48.19
- TRVI $10.90
- Average True Range (ATR)
- CNMD 1.49
- TRVI 0.55
- MACD
- CNMD -0.00
- TRVI 0.02
- Stochastic Oscillator
- CNMD 17.96
- TRVI 99.37
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.